| Today’s Big NewsJun 13, 2024 |
|
Tuesday, June 25, 2024 | 11am ET / 8am PT Expanded Access Programs can help deliver life-saving access to critical medications. Join us for a deep dive into the benefits of EAPs in Europe. Learn how to leverage for achieving faster access to the European market, facilitating successful commercialization, and navigating the array of regulations and guidelines. Register now. 
|
|
| By Angus Liu Pfizer's oncology commercial chief Suneet Varma told Fierce Pharma that the division's plan to have eight blockbusters by 2030 will have contribution from each of its four focused therapeutic areas: breast, genitourinary, hematology and thoracic cancers. |
|
|
|
By Zoey Becker With a phase 3 miss and severe safety signals, Pfizer's Duchenne muscular dystrophy gene therapy candidate is no competition to Sarepta's established Elevidys, according to analysts. |
By Annalee Armstrong A week after an FDA committee declined to support an MDMA treatment for post-traumatic stress disorder, Lykos Therapeutics is looking to dispel some concerns about the therapy as the discussion has taken on a life of its own beyond the biotech world. |
By Conor Hale Vyaire Medical has put up the for-sale sign, as it files for Chapter 11 bankruptcy following drops in demand in the wake of the COVID-19 pandemic. |
|
Wednesday, June 26, 2024 | 2pm ET/ 11am PT In this webinar, we outline a patient-centered telehealth genetic counseling model that accelerates time to meet recruitment goals by engaging and recruiting genetically eligible participants. Certified genetic counselors are uniquely qualified to support the development of a multi-phased approach to patient identification and screening, disclose genetic test results, and more. Register now. 
|
|
By Gabrielle Masson With a former Kite leader at the helm, Santa Ana Bio has unveiled with $168 million and three precision medicine antibodies slated to enter the clinic next year. |
By Andrea Park The amyotrophic lateral sclerosis market is expected to see significant growth in the coming years, but there is still plenty of work to be done within the space, according to a new analyst report. |
By Conor Hale Invizius' H-Guard priming solution coats the inside of a dialysis machine to cloak the hardware from the blood's heightened immune system response. |
By Gabrielle Masson Pfizer’s phase 3 gene therapy trial has failed to demonstrate significant improvement in motor function for boys with Duchenne muscular dystrophy. |
By Kevin Dunleavy J&J has had to deal with two groups of plaintiffs in its talc lawsuits—one that wants to accept a settlement and the other that doesn’t. Now, the latter group has asked a New Jersey federal court to issue a restraining order to block a J&J subsidiary from filing for bankruptcy. |
By James Waldron Barinthus Biotherapeutics has used positive interim data from a pair of phase 2 trials for its hepatitis B therapy as justification for sidelining its prostate cancer candidate and jettisoning a quarter of the T-cell-focused biotech’s workforce. |
By Kevin Dunleavy Eight months after convincing five companies to pay fines to settle antitrust claims, the European Commission has zeroed in on another firm, active pharmaceutical ingredients manufacturer Alchem International, which is accused of engaging in a price-fixing cartel over the key ingredient found in a decades-old antispasmodic drug, Buscopan, and its generic versions. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “The Top Line,” the Fierce Pharma Marketing team discusses the annual top pharma drug ad spenders special report. |
|
|---|
|
|
|
Biotech companies must be able to navigate the complexities of development and approval. Learn how to drive improved speed, quality, predictability, and risk management by making key changes. Download now for exclusive insights. 
|
|
Webinar Watch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
Whitepaper New molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
Whitepaper This paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
